Zobrazeno 1 - 10
of 208
pro vyhledávání: '"Cameron J Turtle"'
Autor:
David Millar, Rebecca Larson, Marcela V Maus, Amanda A Bouffard, Matthew J Frigault, Stefanie R Bailey, Mark B Leick, Michael C Kann, Cameron J Turtle, Trisha Berger, Kathleen Gallagher, Korneel Grauwet, Harrison Silva
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Adoptive cell therapy, such as chimeric antigen receptor (CAR)-T cell therapy, has improved patient outcomes for hematological malignancies. Currently, four of the six FDA-approved CAR-T cell products use the FMC63-based αCD19 single-chai
Externí odkaz:
https://doaj.org/article/ecfec6545a5648c1bf0005393d1e6f09
Autor:
Helen Y Chu, Caitlin R Wolf, Rebecca A Gardner, Cameron J Turtle, Joshua A Hill, Carla S Walti, Andrea N Loes, Kiel Shuey, Elizabeth M Krantz, Jim Boonyaratanakornkit, Jacob Keane-Candib, Tillie Loeffelholz, Justin J Taylor, Damian J Green, Andrew J Cowan, David G Maloney, Steven A Pergam, Jesse D Bloom
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/287ae1b301ef47aab23e2cd038c0f88b
Autor:
Frederick L Locke, Elizabeth J Shpall, Jorg Dietrich, Daniel W Lee, Matthew J Frigault, Terry J Fry, Sara Alexander, Jennifer N Brudno, Colleen Callahan, Marco L Davila, Claudia Diamonte, Julie C Fitzgerald, Jennifer L Holter-Chakrabarty, Krishna V Komanduri, Shannon L Maude, Philip L McCarthy, Elena Mead, David T Teachey, Cameron J Turtle, Tom Whitehead
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disea
Externí odkaz:
https://doaj.org/article/d61d44366994471cbc391339ac6fd898
Autor:
Alexandre V. Hirayama, Cassie K. Chou, Takahiro Miyazaki, Rachel N. Steinmetz, Henna A. Di, Simon P. Fraessle, Jordan Gauthier, Salvatore Fiorenza, Reed M. Hawkins, Willem W. Overwijk, Stanley R. Riddell, Mario Q. Marcondes, Cameron J. Turtle
Publikováno v:
Blood Advances. 7:2479-2493
Chimeric antigen receptor (CAR)–modified T-cell therapies targeting CD19 represent a new treatment option for patients with relapsed/refractory (R/R) B-cell malignancies. However, CAR T-cell therapy fails to elicit durable responses in a significan
Autor:
Daniel J. Landsburg, Matthew Frigault, Michael Heim, Stephen Ronan Foley, Brian T. Hill, Christine M. Ho, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Marta Majdan, Aisha Masood, Marcelo C Pasquini, Cameron J. Turtle
Publikováno v:
Blood. 140:1584-1587
Autor:
Lorena Panaite, Qian 'Vicky' Wu, Jenna Voutsinas, Erin Mullane, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Stephen D. Smith, Ajay K. Gopal, Christina Poh, Lorenzo Iovino, Cameron J. Turtle, David G. Maloney, Brian G. Till, Jordan Gauthier, Mazyar Shadman
Publikováno v:
Leukemia & Lymphoma. 63:2918-2922
Cytopenias are important but less studied adverse events following chimeric antigen receptor-engineered T cell (CAR-T) therapy. In our analysis of patients with large cell lymphoma who received axicabtagene ciloleucel (axi-cel), we sought to determin
Autor:
Jordan Gauthier, Nicolas Gazeau, Alexandre V. Hirayama, Joshua A. Hill, Vicky Wu, Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Victor A. Chow, Ajay K. Gopal, Alexandria Hodges Dwinal, Staci Williamson, Jessie Myers, Andy Chen, Sarah Nagle, Brandon Hayes-Lattin, Levanto Schachter, David G. Maloney, Cameron J. Turtle, Mohamed L. Sorror, Richard T. Maziarz
Publikováno v:
Blood
CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T cells are novel therapies showing great promise for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL). Single-arm studies showed significant varia
Autor:
Cameron J. Turtle, David G. Maloney, Stanley R. Riddell, Kathleen R. Fink, Tahsin Özpolat, Susanna Harju-Baker, Dominic Chung, Junmei Chen, Jose A. Lopez, Mark Wurfel, W. Conrad Liles, Cecilia Yeung, Luis F. Gonzalez-Cuyar, David Myerson, Daniel Li, Laïla-Aïcha Hanafi, Kevin A. Hay, Juliane Gust
Supplementary Figure 4. Activation of HUVECs by serum from patients with neurotoxicity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48b979e4ff59789b75001ea7f489f9c3
https://doi.org/10.1158/2159-8290.22532444
https://doi.org/10.1158/2159-8290.22532444
Autor:
Michael C. Jensen, Leslie S. Kean, Rebecca Gardner, Stanley R. Riddell, Carolina Berger, Bruce R. Blazar, Hannah Brakke, Olivia Finney, Virginia Hoglund, Daniel J. Hunt, Scott N. Furlan, Hengqi Zheng, Alison Yu, Chris English, Audrey Baldessari, Luis Gonzalez-Cuyar, David Myerson, H. Denny Liggitt, Jessica M. Snyder, Cameron J. Turtle, Rafael Ponce, Victor Tkachev, Agne Taraseviciute
CSF and serum levels of 21 cytokines and chemokines measured before and at indicated days after adoptive CD20 CAR T cell transfer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::441d7e1e252feadc79d5376efb380649
https://doi.org/10.1158/2159-8290.22532947.v1
https://doi.org/10.1158/2159-8290.22532947.v1
Autor:
Cameron J. Turtle, David G. Maloney, Stanley R. Riddell, Kathleen R. Fink, Tahsin Özpolat, Susanna Harju-Baker, Dominic Chung, Junmei Chen, Jose A. Lopez, Mark Wurfel, W. Conrad Liles, Cecilia Yeung, Luis F. Gonzalez-Cuyar, David Myerson, Daniel Li, Laïla-Aïcha Hanafi, Kevin A. Hay, Juliane Gust
Supplementary methods, figure legends, and Supplementary Table 1. Lymphodepletion regimens prior to CAR-T cell infusion; Supplementary Table 2. Neurologic adverse event terms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ddb6062ee0a7573f471e592c7470672
https://doi.org/10.1158/2159-8290.22532429.v1
https://doi.org/10.1158/2159-8290.22532429.v1